The Scottish Medicines Consortium (SMC) has approved Ocrevus (ocrelizumab) as a treatment for primary progressive MS in Scotland.
- have had symptoms of primary progressive MS for less than 15 years and
- are able to walk at least 20 metres, with or without walking aids (up to EDSS 6.5) and
- have evidence of MS inflammatory activity on MRI scans
The MS Trust is delighted that Ocrevus has been approved for primary progressive MS. As the first approved treatment for progressive MS in Scotland, this is a landmark decision. But we know this is just the start. More treatments for progressive MS are still desperately needed, and we will continue to fight to ensure everyone with MS can access the treatments they need.
– David Martin, Chief Executive Officer, MS Trust
Ocrevus was approved as a treatment for primary progressive MS in England last year. Roche is working with the NHS in Wales and Northern Ireland to make Ocrevus available throughout the UK. Ocrevus has also been approved as a treatment for relapsing remitting MS in the UK.
Ocrevus is the first treatment to be approved for NHS treatment of primary progressive MS (PPMS). People with this form of MS experience disability more rapidly than those with other types. Clinical trials have shown that Ocrevus can slow the worsening of disability in early, inflammatory PPMS, with the potential to delay the need for a wheelchair by seven years.
Ocrevus is taken as an intravenous infusion (drip). The first dose is given as two separate infusions, two weeks apart. Further doses are given as one infusion every six months. The most common side effects include infusion-related reactions such as headache, rashes, fever and nausea. Other side effects include infections such as coughs, colds, chest infections and herpes virus infections (such as cold sores or shingles).
New report highlights barriers to accessing Sativex across the UK
18 Aug 2021 - 00:00
Fewer than 13% of people in England eligible for Sativex can access it, according to a new report published today. People living in Wales, Scotland and Northern Ireland also face difficulties.
How does MS affect dating and romantic relationships?
2 Aug 2021 - 00:00
This study took an in-depth look at the dating experiences of a small group of people living with MS.
Kesimpta (ofatumumab) approved for relapsing remitting MS in Scotland
12 Jul 2021 - 00:00
The MS Trust is delighted that Kesimpta (ofatumumab) has been approved by SMC for people with active relapsing remitting multiple sclerosis.
Covid boosters and shielding changes for people with MS
21 Sep 2021 - 00:00
From September 2021, the shielding programme for clinically extremely vulnerable people will close. A booster programme will top-up Covid vaccines for vulnerable people.
A sticky situation
13 Sep 2021 - 00:00
For some people with MS, relapses can be a big part of their condition. In this blog, Elaine discusses the unpredictability of multiple sclerosis, including what it feels like to be in a relapse.
Cycling 1,000km for the MS Trust
1 Sep 2021 - 00:00
Fundraiser, George shares his motivations for completing a 1000km cycling challenge on behalf of the MS Trust as well as some useful tips for others thinking of taking on their own physical fundraising challenge.
Sign up for updates from us
Keep up-to-date with the latest MS news, explore new research, read the stories of people living with MS, find out practical tips from MS experts, and discover exciting fundraising opportunities.